ストックスクリーナーアプリを入手
0.1821
2.30%
0.0041
前日終値:
$0.178
開ける：
$0.178
24時間の取引高:
2.79M
Relative Volume:
1.99
時価総額：
$12.13M
収益：
$1.56M
当期純損益:
$-62.68M
株価収益率:
-0.1167
EPS:
-1.56
ネットキャッシュフロー:
$-64.35M
1週間 パフォーマンス:
+1.17%
1か月 パフォーマンス:
-25.37%
6か月 パフォーマンス:
-48.76%
1年 パフォーマンス:
-94.16%
1日の値動き範囲:
$0.1745
$0.1925
1週間の範囲:
$0.1625
$0.2088
52週間の値動き範囲:
$0.1625
$6.79
Lyra Therapeutics Inc Stock (LYRA) Company Profile
LYRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| LYRA | 0.1821 | 12.13M | 1.56M | -62.68M | -64.35M | -1.56 |
| VRTX | 450.10 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.44 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 595.64 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.18 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.06 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-31 | 開始されました | H.C. Wainwright | Buy |
| 2022-05-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-05-26 | 開始されました | BTIG Research | Buy |
| 2020-05-26 | 開始されました | BofA/Merrill | Buy |
| 2020-05-26 | 開始されました | Jefferies | Buy |
| 2020-05-26 | 開始されました | William Blair | Outperform |
すべてを表示
Lyra Therapeutics Inc (LYRA) 最新ニュース
William Blair Has Positive Forecast for LYRA FY2024 Earnings - Defense World
HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World
Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Lyra Therapeutics stock plunges to 52-week low of $0.21 By Investing.com - Investing.com South Africa
Lyra Therapeutics stock plunges to 52-week low of $0.21 - Investing.com India
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates - MSN
Lyra Therapeutics Inc (LYRA) Q3 2024 Earnings: Net Loss of $11.9M, Misses EPS and Revenue Estimates - GuruFocus.com
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Lyra Therapeutics Reports Strong Safety Data, Cuts Q3 Losses by 24% as LYR-210 Advances | LYRA Stock News - StockTitan
Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) PT at $4.50 - Defense World
Chronic Rhinosinusitis Market: Driving Rapid Growth with Top - openPR
Lyra Therapeutics Inc (NASDAQ: LYRA) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
Lyra Therapeutics completes Phase 3 trial enrollment for CRS treatment By Investing.com - Investing.com Canada
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - The Manila Times
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 - GlobeNewswire
Market Momentum: Lyra Therapeutics Inc (LYRA) Registers a 3.08 Increase, Closing at 0.24 - The Dwinnex
Lyra Therapeutics Inc (LYRA)’s stock price in review: A technical analysis - US Post News
Lyra Therapeutics Inc: Navigating a Turbulent Year, Up -96.61% from 52-Week Low - The InvestChronicle
Lyra Therapeutics stock plunges to 52-week low of $0.24 - Investing.com
Lyra Therapeutics stock plunges to 52-week low of $0.24 By Investing.com - Investing.com UK
What is the investor’s view on Lyra Therapeutics Inc (LYRA)? - US Post News
The time has not yet come to remove your chips from the table: Lyra Therapeutics Inc (LYRA) - SETE News
Where Do Analysts Think The Lyra Therapeutics Inc (NASDAQ: LYRA) Is Going - Stocks Register
Lyra Therapeutics Inc (LYRA) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Lyra Therapeutics to Present Study Results for LYR-210 and - GlobeNewswire
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings - StockTitan
Lyra Therapeutics stock plunges to 52-week low of $0.25 By Investing.com - Investing.com South Africa
Lyra Therapeutics stock plunges to 52-week low of $0.25 - Investing.com
Market Recap: Lyell Immunopharma Inc (LYEL)’s Positive Momentum, Closing at 1.46 - The Dwinnex
XTX Topco Ltd Invests $500,000 in Lindsay Co. (NYSE:LNN) - MarketBeat
Great Point Partners LLC Purchases New Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Defense World
Understanding LXRX’s book value per share for better investment insights - US Post News
All You Need to Know About Tyler Technologies (TYL) Rating Upgrade to Buy - Yahoo Finance
Upward Trajectory: Lexicon Pharmaceuticals Inc (LXRX) Posts a Slidee, Closing at 1.58 - The Dwinnex
Lyell Immunopharma Inc (LYEL)’s stock price in review: A technical analysis - US Post News
Intech Investment Management LLC Buys 1,502 Shares of Tyler Technologies, Inc. (NYSE:TYL) - MarketBeat
Citigroup Acquires Substantial Stake in Syrah Resources - TipRanks
Analysts review Tyler Technologies, Inc.’s rating - Knox Daily
Ratio Examination: Lyra Therapeutics Inc (LYRA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Tyler Technologies, Inc. (NYSE:TYL) Receives $582.31 Average Target Price from Analysts - MarketBeat
GILD: 3 Biotech Stocks to Watch as FDA Approvals Roll In - StockNews.com
There is no doubt that Lyra Therapeutics Inc (LYRA) ticks all the boxes. - SETE News
Renaissance Technologies LLC Acquires 291,000 Shares of LXP Industrial Trust (NYSE:LXP) - Defense World
Acadian Asset Management LLC Makes New Investment in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Are Lyra Therapeutics Inc (LYRA) shares a good deal now? - US Post News
Ratio Revelations: Lyra Therapeutics Inc (LYRA)’s Financial Metrics in the Spotlight - The Dwinnex
The Psychology of Lyra Therapeutics Inc Inc. (LYRA) Price Performance: Understanding Market Sentiment - The InvestChronicle
Taking the lead: Lyra Therapeutics Inc (LYRA) - SETE News
Lyra Therapeutics Inc (LYRA) stock analysis: A simple moving average approach - US Post News
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Given Consensus Rating of “Hold” by Analysts - Defense World
Lyra Therapeutics Inc (LYRA)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Lyra Therapeutics Inc (LYRA) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):